This study is currently not recruiting participants.

Treating Multidrug Resistant Non-Tuberculous Mycobacterial Disease with Clofazimine

Study on Investigational Medication for Multidrug Resistant Nontuberculous Mycobacterial (NTM) Infections

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to provide access to clofazimine for the treatment of multidrug resistant NTM.

Detailed description of study

The purpose of this study is to provide access to clofazimine for the treatment of multidrug resistant NTM.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Tuberculous Mycobacterial Disease
  • Age: 100 years or below
  • Gender: All

This study investigates the use of an investigational medication for treating multidrug resistant NTM (nontuberculous mycobacterial) infections. NTM are a group of bacteria that can cause lung infections, especially in people with weakened immune systems or existing lung conditions.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.

  • Who can participate: Participants must meet specific age criteria and have a diagnosis of multidrug resistant NTM infection. Additional eligibility factors include having a weakened immune system or existing lung conditions.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1601443670

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team